monomorphic epitheliotropic intestinal T-cell lymphoma

Summary

monomorphic epitheliotropic intestinal T-cell lymphoma (MONDO:0958096) is a cancer and 7 clinical trials. Top therapeutic interventions include duvelisib, pembrolizumab, and pralatrexate. A subtype of T-cell non-Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	monomorphic epitheliotropic intestinal T-cell lymphoma
Mondo ID	MONDO:0958096
Orphanet	652658
NCIT	C96058
UMLS	C3272525
MedGen	474158
GARD	0026927
Is cancer (heuristic)	yes

Disease family

This is a subtype of T-cell non-Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › lymphoma › non-Hodgkin lymphoma › T-cell non-Hodgkin lymphoma › monomorphic epitheliotropic intestinal T-cell lymphoma

Related subtypes (8): mature T-cell and NK-cell non-Hodgkin lymphoma, primary cutaneous T-cell lymphoma, CD4+/CD56+ hematodermic neoplasm, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, hepatosplenic T-cell lymphoma, T-lymphoblastic lymphoma, Nodal T-follicular helper cell lymphoma, follicular type

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1/PHASE2	2
PHASE2	2
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03598998	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
NCT05475925	PHASE1/PHASE2	RECRUITING	A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
NCT04803201	PHASE2	SUSPENDED	Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
NCT06692452	PHASE2	WITHDRAWN	Tazemetostat Plus CHOP in 1L T-cell Lymphoma
NCT05377827	PHASE1	ACTIVE_NOT_RECRUITING	Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
NCT07388563	PHASE1	SUSPENDED	Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
NCT05978141	Not specified	RECRUITING	A Registry for People With T-cell Lymphoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DUVELISIB	4	1
PEMBROLIZUMAB	4	1
PRALATREXATE	4	1
TAZEMETOSTAT	4	1
DIBOTATUG	2	1
CHEMBL3805348	0	1
CHEMBL4538684	0	1
CHEMBL5398431	0	1